<DOC>
	<DOCNO>NCT01656200</DOCNO>
	<brief_summary>Japanese encephalitis ( JE ) live attenuate vaccine SA14-14-2 use 20 year Asia . JE vaccine SA14-14-2 license India widely use since 2006 . JE vaccine give protection generate neutralize antibody response , naturally expose person patient JE also T cell response . Whether JE vaccine SA14-14-2 elicit T cell response unknown . This study test hypothesis T cell response generate response JE SA14-14-2 vaccination . The aim study characterize T cell response JE vaccine SA14-14-2 healthy people , investigate difference T cell responses natural exposure , vaccination disease .</brief_summary>
	<brief_title>A Prospective , Open Label Study Human T Cell Responses Live Attenuated Japanese Encephalitis Vaccine SA14-14-2</brief_title>
	<detailed_description />
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : A male female adult 18 50 year age . Written informed consent . Free obvious health problem establish medical history history direct physical examination enter study . Expected continuous residence India study period , without travel outside India An efficacious method contraception must use study woman childbearing potential . Use investigational nonregistered drug vaccine study vaccine within 30 day precede administration SA14142 vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within period six month vaccination time study period . Any confirm suspected immunosuppressive immunodeficient condition . A family history congenital hereditary immunodeficiency . Any antiviral drug therapy within period six month vaccination time study period . History significant allergic disease reaction likely exacerbate component study vaccine , especially allergic disease reaction previous dose vaccine . History receive JE vaccine , yellow fever vaccine , tickborne encephalitis vaccine experimental flavivirus vaccine . History document JE infection . Detectable anti JE West Nile neutralize antibody screen test . Acute disease time enrollment . Entry study may defer illness resolve . Acute chronic , clinically significant , pulmonary , cardiovascular , hepatic , neurological renal functional abnormality , determine history physical laboratory examination control drug . Administration immunoglobulins and/or blood product within three month precede administration vaccine , plan administration study period . Seropositive HIV , HCV HbsAg . Lactation , pregnancy intention get pregnant . History excessive alcohol consumption , drug abuse significant psychiatric illness . Any condition opinion investigator would pose health risk participant interfere evaluation vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Japanese encephalitis</keyword>
	<keyword>Japanese encephalitis vaccine</keyword>
	<keyword>T lymphocyte</keyword>
	<keyword>Immune response</keyword>
</DOC>